Alex Dusek Email & Phone Number

Durham, Nc, Us

Prepare for the commercial launch of the first Hyperpolarized Xenon MRI drug/device combination, should the registration of this novel functional lung imaging modality be successful.

Lyon, Rhône-Alpes, Fr

ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), is a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells. As the commercial leader on the executive team, I was preparing the launch readiness framework for potential success of late-stage cell therapy drug product candidates worldwide, with initial focus on the United States.

Argos was a pre-commercial stage public biotech company based on a precision medicine immunotherapy platform. Reporting directly to the CEO, I was charged with leading the overall commercialization strategy for the potential launch of Rocapuldencel-T (AGS-003), our lead precision immuno-oncology agent and leading the cross-functional product launch team towards successful analysis of Phase III data, BLA submission, and launch of this first-in-class cell therapy.Developed the commercialization plan including product forecasts for launch and oncology LCM indications, including all inputs into product P&L• Created novel hub service model of tissue collection, manufacturing and distribution of cryopreserved doses with 3PL and specialty pharmacy providers for integrated delivery an autologous cell therapy• Drove biomarker and companion diagnostic strategy by assessing biomarkers from tumor, plasma and PBMCs that might predict treatment mediated effects for analysis of phase III trial and further enrich potential entry population in future trials• Rebranded company and platform as “Precision Immunotherapy” including print and digital campaign• Collaborated with the business development leader to assess collaboration opportunities in oncology and virology, including academic, industry, and NIH partners• Formed and led the first integrated Product Launch Team, linking cross-functional activities and dependencies, to develop project plan with key milestones, and KPIs for BLA and launch• Led formation of publication strategy team and managed the publication plan as well as thought-leader mapping activities, including field MSL sizing and hiring plan in collaboration with Chief Medical Officer• Developed the hiring plan for entire commercial infrastructure, including marketing, sales, and market access functions required to support the global launch, the full activation of which would trigger at successful outcome of blinded Phase III trial

Leverkusen, North Rhine-Westphalia, De

- Lead the preparation of the launch strategy for Riociguat, the first of new class of investigational Pulmonary Hypertension compounds developed by Bayer Scientists. This includes developing the brand strategy for the initial target indications in Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH), as well as assessment of life-cycle opportunities PH related to lung disease such as Chronic Obstructive Lung Disease (PH-COPD) and Idiopathic Pulmonary Fibrosis (PH-IPF), and left-ventricle dysfunction (PH-LVD). - Responsible for integrating business unit perspectives on marketing plan from all key countries represented on the Global Launch Team, and aligning strategies led by global clinicial development and medical affars colleagues in Phase IIIb/IV clinical trial, health economic outcomes research and publication planning.

Silver Spring, Maryland, Us

2007 to 2010Oversaw annual sales and marketing plans and for entire Pulmonary Arterial Hypertension (PAH) portfolio growing revenue over 30% for past several years and quartersBuilt and developed an entire marketing team of six direct reports as well as spearheaded several cross-functional sales training, commercial informatics, and managed markets initiativesServed as the executive marketing representative on four-person deal team responsible for securing the Sales and Marketing license for tadalafil (Cialis) from Lilly for the Pulmonary Hypertension indication in the US for $150MLed launch of Adcirca in July 2009, only 8 months after signing deal rapidly achieving 17% market share of PDE5 marketAwarded 2008 Presidents Award for Innovation for novel approach to consumer-oriented promotional and support programs setting new standards in PAH cardiovascular arenaRevived Remodulin, the company's mainstay brand launched in 2002, increasing revenue from $160M to $300M in 3 years without any price increases, by designing new marketing strategy, re-orienting sales force, integrating Lung Rx subsidiary sales organization, and creating new regional clinical specialist roles for shared fields sales team optimization.Received the prestigious annual "Building Block" Award, given by the field sales organization to the single member from the headquarters support teams, across multiple functions, who provided the most value to field sales organization throughout the yearLed the strategic life cycle planning efforts for the entire product portfolio including marketed and development-stage products as part of executive management team responsible for long-term strategic planning

Us

Started Trimeris marketed function at the end of phase II and was responsible for establishing entire marketing department including recruitment and hiring of direct reports in product management, public and investor relations.Responsible for strategic marketing and integrated communication plan for the launch of Fuzeon, the first of a novel class of HIV/AIDS drugs that inhibit virus entry* Wrote and led execution of annual US marketing plans and 5 year Life Cycle Strategic PlanAuthored several publications on cost-effectiveness of HIV combination regimens and patient reported outcomes (patient satisfaction, QOL, and impact on ADL) in support of reimbursement strategy across private and government payor organizations.Served as Trimeris lead on the International Business Team and co-authored the Global Strategic Launch Concept with Roche global brand leaderCreated the brand name, led development of logo and art style guide for country affiliatesOversaw PR agency instrumental in securing major media placements for Fuzeon and capitalized on the pre-launch product interest to elevate the corporate profile of TrimerisUtilized ongoing market analytics, as well as input from key customers in advisory boards to create and refine medical messages and product positioning, coordinating ad agency brand positioning, development and creative outputTrained Roche division managers, sales representatives and clinical liaisons on product positioning and Trimester plans of actions Managed Trimeris marketing staff to develop online innovative consumer-oriented marketing strategy including launch of product web site, sponsorship of 3rd party websites and novel nurse educator patient support program, "Fuzeon Connections"Led product directors and ad agency in creative development of physician journal advertising, new class advertorials, and sales tools

Ingelheim Am Rhein, Rhineland-Palatinate, De

Led the U.S. Launch of Viramune, the first of a novel class of HIV/AIDS drugs, and represented U.S. affiliate on core global marketing team * Designed new functions in sales organization for community activist liaisons and HIV specialists, including job description, qualifications and roles and responsibilities in order to support product launch* Spearheaded the launch of the first generic Azathioprine including setting pricing and distribution strategy and exceeded target sales

* Awarded national representative of the year 1994****Led sales in academic teaching institutions calling on oncologists, HIV, and pain management specialists

* Achieved highest rank in region for sales for pain management and cardiovascular products

Mba, Marketing

Postbaccalaureate Premedical Program, Pgpm

B.A, Linguistics

Bachelors, Linguistics